特利加压素联合前列地尔辅助腹水超滤浓缩回输治疗肝硬化并发难治性腹水患者疗效分析*

doi:10.3969/j.issn.1672-5069.2020.02.024

摘要/Abstract

摘要： 目的探讨应用特利加压素联合前列地尔辅助腹水超滤浓缩回输治疗肝硬化并发难治性腹水患者的临床效果。方法 2017年3月～2018年6月我院感染病科住院治疗的104例肝硬化并发难治性腹水患者被随机分为腹水回输治疗组52例和综合治疗组52例,分别给予腹水超滤浓缩回输腹腔治疗,综合治疗组则在此基础上加用前列地尔和特利加压素治疗。观察6个月。结果治疗后一周,综合治疗组门静脉血流速度(Vpv)和脾静脉血流速度(Vsv)分别为(25.6±1.5)cm/s和(27.3±2.7)cm/s,显著快于腹水回输组【分别为(21.4±1.3)cm/s和(25.4±2.1)cm/s, P<0.05】;治疗后,综合治疗组血清一氧化氮、内皮素-1和内毒素水平分别为(13.4±2.1)μmol/L、(53.2±10.3)pg/mL和(31.4±13.2)pg/mL,与腹水回输组【分别为(16.2±2.3)μmol/L、(68.3±12.6)pg/mL和(49.5±14.1)pg/mL,P<0.05】比,差异显著;治疗后,综合治疗组腹围、腹水量和24 h尿量分别为(98.6±7.2)cm、(35.2±9.3)mm和(1531.4±234.2)mL,与腹水回输组【分别为(102.7±6.4)cm、(48.3±11.5)mm和(1249.5±215.1)mL, P<0.05】比,差异显著;治疗后6个月,综合治疗组腹水消退35例(67.3%),显著高于腹水浓缩回输组的14例(26.9%,P<0.05)。结论应用特利加压素联合前列地尔辅助腹水超滤浓缩回输腹腔治疗肝硬化并发难治性腹水患者具有较好的临床治疗效果,可显著改善患者血液微循环和肝肾功能,有助于促进腹水消退,维持疗效。

关键词: 肝硬化, 难治性腹水, 腹水超滤浓缩回输, 前列地尔, 特利加压素, 治疗

Abstract: Objective The aim of this study was to investigate the clinical efficacy of ultrafiltration, concentration and reinfusion of ascites (UCRA) and alprostadil and terlipressin combination in treatment of patients with cirrhosis complicated by refractory ascites (RA). Methods 104 patients with cirrhosis complicated with RA were recruited in the Department of Infectious Diseases in our hospital between March 2017 and June 2018, and were randomly divided into two groups, with 52 in each, receiving UCRA and synthetical treatment, e.g. combination of UCRA and intravenous administration of alprostadil and terlipressin. All patients were followed-up for six months. Results At the end of one week treatment, the velocity of main portal vein and velocity of splenic vein in synthetical treatment group were (25.6±1.5)cm/s and (27.3±2.7)cm/s, significantly rapider than 【(21.4±1.3)cm/s and (25.4±2.1)cm/s, respectively, P<0.05】 in patients receiving UCRA treatment alone; serum nitric oxide (NO), endothelin-1 (ET-1) and endotoxin were (13.4±2.1)μmol/L, (53.2±10.3)pg/mL and (31.4±13.2)pg/mL,significantly different as compared to 【(16.2±2.3)μmol/L, (68.3±12.6)pg/mL and (49.5±14.1)pg/mL, respectively, P<0.05】 in UCRA-treated groups; the abdominal circumference, ascites depth and urine volume/24 h were (98.6±7.2)cm,(35.2±9.3)mm and (1531.4±234.2)mL, significantly different as compared to [(102.7±6.4)cm, (48.3±11.5)mm and (1249.5±215.1)mL,respectively, P<0.05】 in thesubsided rate in the latter; at the end of six month observation, the ascites synthetical treatment group was 67.3%, significantly higher than 26.9% in the UCRA-treated group (P<0.05). Conclusion The application of alprostadil and terlipressin might assist ultrafiltration, concentration and reinfusion of ascites in treatment of patients with liver cirrhosis and RA, and the long-term efficacy should be observed.

Key words: Liver cirrhosis, Refractory ascites, Alprostadil, Terlipressin, Ultrafiltration, concentration and reinfusion of ascites, Therapy

张惠勇, 吴秀欣, 徐成润. 特利加压素联合前列地尔辅助腹水超滤浓缩回输治疗肝硬化并发难治性腹水患者疗效分析^*[J]. 实用肝脏病杂志, 2020, 23(2): 244-247.

Zhang Huiyong, Wu Xiuxin, Xu Chengrun. Clinical efficacy of ultrafiltration, concentration and reinfusion of ascites and alprostadil and terlipressin combination in treatment of patients with cirrhosis complicated by refractory ascites[J]. Journal of Practical Hepatology, 2020, 23(2): 244-247.

参考文献

[1] Zhao R, Lu J, Shi Y, et al. Current management of refractory ascites in patients with cirrhosis. J Int Med Res, 2018, 46(3): 1138-1145.
[2] Piano S, Tonon M, Angeli P. Management of ascites and hepatorenal syndrome. Hepatol Int, 2018, 12(1): 122-134.
[3] Pose E, Cardenas A. Translating our current understanding of ascites management into new therapies for patients with cirrhosis and fluid retention. Dig Dis, 2017, (4): 402-410.
[4] Saffo S, Taddei T. Sglt2 inhibitors and cirrhosis: a unique perspective on the comanagement of diabetes mellitus and ascites. Clin Liver Dis (Hoboken), 2018, 11(6): 141-144.
[5] Togami S, Hori S, Kamio M, et al. Clinical usefulness of concentrated ascites reinfusion therapy (cart) for gynecological cancer patients with refractory massive ascites due to cancerous peritonitis. Eur J Gynaecol Oncol, 2014, (3): 301-303.
[6] Wen X1, Yao M2, Lu Y3, et al. Integration of prealbumin into child-pugh classification improves prognosis predicting accuracy in hcc patients considering curative surgery. J Clin Transl Hepatol, 2018, 6(4): 377-384.
[7] Aday AW, Rich NE, Mufti AR, et al. Con ("the window is closed"): in patients with cirrhosis with ascites, the clinical risks of nonselective beta-blocker outweigh the benefits and should not be prescribed. Clin Liver Dis (Hoboken), 2018, 11(5): 123-127.
[8] Yamada Y, Yamaguchi A, Harada M, et al. Protein concentration of refractory ascites in cancer patients is reflected by the presence and severity of peritoneal and liver metastasis. Ther Apher Dial, 2017, 21(3): 263-269.
[9] Tholey D, Roth N, Schiano T. Pro ("the window is open"): in patients with cirrhosis with prior variceal hemorrhage and ascites, the clinical benefits of nonselective beta-blockers outweigh the risks and should be prescribed. Clin Liver Dis (Hoboken), 2018, 11(5): 119-122.
[10] Iseki M, Kushida Y, Wakao S, et al. Muse cells, nontumorigenic pluripotent-like stem cells, have liver regeneration capacity through specific homing and cell replacement in a mouse model of liver fibrosis. Cell Transplant, 2017, 26(5): 821-840.
[11] Papaluca T, Gow P. Terlipressin: Current and emerging indications in chronic liver disease. J Gastroenterol Hepatol, 2018, 33(3): 591-598.
[12] Patil V, Jain M, Venkataraman J. Paracentesis-induced acute kidney injury in decompensated cirrhosis-prevalence and predictors. Clin Exp Hepatol, 2019, 5(1): 55-59.
[13] Srinivas NR. Prostaglandin e1 therapy with alprostadil and risk reduction in early hepatic cellular carcinoma after liver transplantation. Aliment Pharmacol Ther, 2016, 43(1): 172-173.
[14] Karaaslan P, Sevmis S. Effect of terlipressin infusion therapy on recipient's hepatic and renal functions in living donor liver transplantations: experience from a tertiary hospital. Niger J Clin Pract, 2019, (2): 265-269.
[15] Hammond JS, Godtliebsen F, Steigen S, et al. The effects of terlipressin and direct portacaval shunting on liver hemodynamics following 80% hepatectomy in the pig. Clin Sci (Lond), 2019, 133(1): 153-166.
[16] 王磊. 手术治疗胆石症并发急性胰腺炎患者血清炎症和氧化应激介质的变化. 实用肝脏病杂志, 2018, 21(2): 273-276.
[17] Lenz K,Buder R,Kapun L,et al.Treatment and management of ascitesand hepatorenal syndrome:an update.Therap Adv Gastroenterol,2015,8(2): 83-100.
[18] 徐小元, 丁惠国, 李文刚, 等. 肝硬化腹水及相关并发症的诊疗指南. 实用肝脏病杂志, 2018, 21(1): 21-31.

特利加压素联合前列地尔辅助腹水超滤浓缩回输治疗肝硬化并发难治性腹水患者疗效分析^*

Clinical efficacy of ultrafiltration, concentration and reinfusion of ascites and alprostadil and terlipressin combination in treatment of patients with cirrhosis complicated by refractory ascites

PDF (PC)

可视化

摘要/Abstract

引用本文

使用本文

参考文献

相关文章 15

编辑推荐

Metrics

本文评价

[1]	温博, 王炳元. Wilson’s病:一个潜在的可治疗的遗传性疾病^*[J]. 实用肝脏病杂志, 2020, 23(2): 156-158.
[2]	周翠梅, 胡立芬, 李家斌, 储雪琴, 郜玉峰. 思维导图在慢性乙型肝炎患者管理中应用价值研究^*[J]. 实用肝脏病杂志, 2020, 23(2): 187-190.
[3]	张晓伟, 钟蕊. 索磷布韦和维帕他韦联合利巴韦林治疗基因2、3型慢性丙型肝炎患者近期疗效和耐受性观察^*[J]. 实用肝脏病杂志, 2020, 23(2): 191-194.
[4]	贾晨, 张涛, 王浩, 戚凤君. 利拉鲁肽治疗非酒精性脂肪性肝病合并2型糖尿病患者血脂、血管内皮功能和肝纤维化指标的变化^*[J]. 实用肝脏病杂志, 2020, 23(2): 203-206.
[5]	王红学, 朱清静, 张玉娟, 毛重山. 异甘草酸镁联合乙酰半胱氨酸治疗药物性肝损伤患者血清氧化应激指标的改变^*[J]. 实用肝脏病杂志, 2020, 23(2): 227-230.
[6]	张玉玲, 周瑾, 董宏伟. 超声点定量弹性成像技术对AIH和PBC患者肝纤维化诊断价值分析^*[J]. 实用肝脏病杂志, 2020, 23(2): 231-235.
[7]	李永超, 任红军, 刘磊, 张松. 双重血浆吸附联合血浆置换治疗慢加急性乙型肝炎肝衰竭患者临床疗效研究^*[J]. 实用肝脏病杂志, 2020, 23(2): 236-239.
[8]	贾娇, 王芳, 张波, 武琼. 熊去氧胆酸联合骨化三醇治疗原发性胆汁性肝硬化患者疗效和外周血T淋巴细胞亚群的变化^*[J]. 实用肝脏病杂志, 2020, 23(2): 240-243.
[9]	阿思根, 夏医君, 武慧军, 薛荣泉, 辛瑞强, 白斯古楞, 赵德芳. 脾切除术联合门奇静脉断流术治疗肝硬化门脉高压症患者疗效研究^*[J]. 实用肝脏病杂志, 2020, 23(2): 248-251.
[10]	胡星, 孟繁坤, 韩晶, 张旭辉. 应用超声心动图评估肝硬化患者心脏结构和功能临床价值研究^*[J]. 实用肝脏病杂志, 2020, 23(2): 252-255.
[11]	邢乐康, 邓永东, 姚立琼, 金凤玲. 乙型肝炎肝硬化患者肠道菌群变化研究^*[J]. 实用肝脏病杂志, 2020, 23(2): 256-259.
[12]	范建高. 不忘初心,砥励前行[J]. 实用肝脏病杂志, 2020, 23(1): 1-1.
[13]	陈从新, 王莉苹. 应用皮质激素治疗肝衰竭存在什么争议？[J]. 实用肝脏病杂志, 2020, 23(1): 2-3.
[14]	徐小元. 解读肝硬化诊治指南难点与新颖之处[J]. 实用肝脏病杂志, 2020, 23(1): 4-6.
[15]	范文瀚, 罗怡平, 李成忠. 糖皮质激素应用于肝衰竭治疗机制及其临床时机的把握[J]. 实用肝脏病杂志, 2020, 23(1): 7-9.